- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04746781
The Effect of 360 Video and MAPS on Enrollment in the DPP
The Effect of Mobile Immersive Video and Motivation and Problem Solving on Enrollment in the Diabetes Prevention Program
Study Overview
Status
Conditions
Detailed Description
More than 88 million Americans are at risk of developing Type 2 diabetes mellitus (T2DM). The one-year Diabetes Prevention Program (DPP) has been shown to be effective in reducing the risk of progressing from prediabetes to T2DM. However, most individuals who could benefit from the program never enroll.
Prior research has elucidated several reasons people do not enroll in the DPP. First, many people are not aware that they are at risk of developing T2DM, or that an efficacious program like the DPP exists. Second, the complications from T2DM are abstract, distal and difficult to imagine, which in turn leads to low motivation for risk-reducing behaviors. Finally, practical barriers limit DPP enrollment including cost, travel time, and scheduling. Prior research has tested rational appeals (such as provider-based education and referral) to enroll individuals in the DPP, with limited efficacy. In this project we will compare the effects of notification and education alone, notification and education plus mobile phone delivered videos (emotional appeal), and notification and education plus phone-based coaching utilizing a motivation and problem-solving approach. Our primary outcome will be enrollment and 1-month engagement in the DPP.
This three-armed randomized, clinical trial will be conducted within 2 health systems. Following an opt-out procedure offered to all eligible participants, participants will complete informed consent and a baseline survey. In the risk notification/education arm, we will send all participants a short message service (SMS) message with a link to a website that educates the public about their risk for developing T2DM and about the availability and efficacy of the DPP to address their risk. In the Mobile 360° Video intervention arm, after risk notification/education, participants will receive links to two 3-minute immersive Mobile 360° Videos (in which the viewer moves their phone to 'look around' the world of the video) on their smart phones. These videos are intended to influence affective and experiential perceptions of risk. The first video tells an emotional story of the negative effects on an individual's health and family life as they progress from prediabetes to T2DM and develop cardiovascular complications. The second video provides the viewer with a vicarious experience of the changes in vision that occur as diabetic retinopathy develops and worsens.
In the Motivation and Problem Solving (MAPS) arm, after risk notification/education, participants will be called by a health coach trained in counseling/coaching. The coach will guide them in setting health related goals and addressing any practical barriers to enrolling/engaging in the DPP, if that is consistent with their health goals.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Utah
-
Salt Lake City, Utah, United States, 84108
- University of Utah
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Are aged 18-89
- Have a diagnosis of prediabetes within the past 5 years (ICD-10 code R73.03)
- Have an email and mobile telephone number on record with the Health-system
- Primary language of either English or Spanish
Exclusion Criteria:
- Type 2 diabetes mellitus (ICD-10-CM E11);
- Type 1 diabetes mellitus (ICD-10-CM Diagnosis E10),
- Diabetes mellitus due to underlying condition (ICD-10 E08);
- Drug or chemical induced diabetes mellitus (ICD-10 E09);
- Gestational diabetes (ICD-10 024.4);
- Neonatal diabetes mellitus (ICD-10 P70.2);
- Post-pancreatectomy diabetes mellitus (ICD-10 E13).
- Patients whose primary language is other than Spanish or English will be excluded.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Risk notification/education arm
We will send all participants a short message service (SMS) message with a link to a website that educates the public about their risk for developing T2DM and about the availability and efficacy of the DPP to address their risk
|
Sending participants (all of whom meet the diagnostic criteria for prediabetes) educational information about the condition.
|
|
Experimental: Mobile 360° Video intervention arm
After risk notification and education, participants will receive links to two 3-minute immersive Mobile 360° Videos (in which the viewer moves their phone to 'look around' the world of the video) on their smart phones.
These videos are intended to influence affective and experiential perceptions of risk.
The first video tells an emotional story of the negative effects on an individual's health and family life as they progress from prediabetes to T2DM and develop cardiovascular complications.
The second video provides the viewer with a vicarious experience of the changes in vision that occur as diabetic retinopathy develops and worsens.
|
Sending participants (all of whom meet the diagnostic criteria for prediabetes) educational information about the condition.
Using 360° Videos to educate participants about the effect of diabetes.
|
|
Experimental: Motivation and Problem Solving (MAPS) arm
After risk notification and education, participants will be called by a health coach trained in counseling/coaching.
The coach will guide them in setting goals related to their health, and addressing any practical barriers to enrolling/engaging in the DPP if that is consistent with their health goals.
Per their preference, participants will receive up to 5 phone calls from the health coach over a 4 week period.
|
Sending participants (all of whom meet the diagnostic criteria for prediabetes) educational information about the condition.
Using Motivation and Problem Solving to help people enroll in the Diabetes Prevention Program.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Diabetes prevention program enrollment
Time Frame: 1-month
|
Enrollment in the Diabetes prevention program .
This data that is recorded by all Diabetes prevention programs and is required to be reported to the Centers for disease control.
For individuals attending an in person-class.
It is defined by the CDC as registration for the program.
For individuals who enroll in an online DPP it is defined by the CDC as an individual setting their password for the app.
For the purposes of this trial any individual meeting either of these criteria will be considered to have enrolled in the DPP.
|
1-month
|
|
4 weeks of engagement in the Diabetes prevention program
Time Frame: 1 month
|
1-month engagement in the Diabetes prevention program. This is data that is recorded by all Diabetes prevention programs and is required to be reported to the Centers for Disease Control. For individuals attending an in person-class, it is defined by the CDC as the individual attending at least 2 of the first four sessions. For individuals who enroll in an online DPP it is defined by the CDC as completing at least two of the following activities: (A) Complete two education modules (B) Send at least 1 In-App message and/or Group Wall post (C) Set or log at least one behavior (D) Log, plan or research at least three meals (E) Log physical activity at least three (F) Weigh-in on three or more days in two out of the first four weeks For the purposes of this trial any individual meeting either of these criteria will be considered to have engaged in the DPP for the first month. |
1 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in self-efficacy
Time Frame: 1 month
|
Self-efficacy related to Diabetes prevention program participation as well as diet, exercise, and weight loss will be measured using the brief (16 items) Self-Efficacy scales adapted from Wilson 2016: Wilson KE, Harden SM, Almeida FA, et al. Brief self-efficacy scales for use in weight-loss trials: Preliminary evidence of validity. Psychological assessment 2016; 28(10): 1255-64. This will be measured pre and post intervention and the change score calculated and compared across intervention arms |
1 month
|
|
Changes in Risk perceptions
Time Frame: 1 month
|
Risk perceptions related to development of Type 2 Diabetes will be measured using an 18-item measure of risk perceptions for Type 2 diabetes developed by Ferrer et al: Ferrer RA, Klein WMP, Persoskie A, Avishai-Yitshak A, Sheeran P. The Tripartite Model of Risk Perception (TRIRISK): Distinguishing Deliberative, Affective, and Experiential Components of Perceived Risk. Annals of Behavioral Medicine 2016; 50(5): 653-63. This measure includes 6 items each to measure three different aspects of risk perception: deliberative, affective and experiential risk perceptions. we will calculate the sub scores for these dimensions and compare changes in them across intervention arms |
1 month
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 00132307
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
University of North Carolina, Chapel HillAmerican Heart AssociationRecruitingType 2 Diabetes | Nutrition | Diabetes Type 2 | T2DM (Type 2 Diabetes Mellitus) | Diabetes Mellitis | T2DM | Diabetes EducationUnited States
-
ENBIOSIS BIOTECHNOLOGIESAydin Adnan Menderes University; Izmir University of Economics; Buca Seyfi Demirsoy... and other collaboratorsNot yet recruitingType 2 Diabetes | Diabetes Mellitus Type 2Turkey (Türkiye)
-
Instituto Nacional de Ciencias Medicas y Nutricion...Active, not recruiting
-
Endogenex, Inc.Not yet recruitingDiabetes Mellitus, Type 2 | Diabetes | Type 2 Diabetes Mellitus | Type 2 Diabetes | Type2diabetes
-
University of SalamancaUniversity of Salamanca; Instituto Piaget; Escola Superior de Tecnologia da Saúde...Enrolling by invitationType 2 Diabetes Mellitus | Aging | Hyperglycemia Due to Type 2 Diabetes MellitusPortugal
-
Endogenex, Inc.Not yet recruitingDiabetes Mellitus, Type 2 | Diabetes | Type 2 Diabetes | Type 2 Diabetes Mellitus (T2DM) | Type2Diabetes
-
University of Colorado, DenverMassachusetts General Hospital; Ann & Robert H Lurie Children's Hospital of... and other collaboratorsRecruitingDiabetes Mellitus | Diabetes | Type 2 Diabetes | Diabetes Mellitus Type 2 | Diabetes Mellitus, Type I | Diabetes Mellitus Type II | Diabetes Mellitus, Insulin-Dependent | Diabetes, Autoimmune | Type 1 Diabetes (T1D) | Diabetes Type 2 on Insulin | Diabetes, Type IIUnited States
-
Kaiser PermanenteThe Permanente Medical GroupEnrolling by invitationType 2 Diabetes | Type 2 Diabetes Mellitus (T2DM) | Type 2 Diabetes (T2D)United States
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Steno Diabetes Center CopenhagenRecruitingDiabetes | Cognitive Impairment | Type 2 Diabetes | Diabetes Mellitus Type 2 | Cognitive Decline | Type 2 Diabetes Mellitus (T2DM)Denmark
Clinical Trials on Risk notification/education
-
Vanderbilt University Medical CenterCompletedAcute Kidney Injury | Kidney Disease | Renal InjuryUnited States
-
Seoul St. Mary's HospitalSaint Vincent's Hospital, Korea; Uijeongbu St. Mary HospitalCompletedColonoscopy | Human CharacteristicsKorea, Republic of
-
Massachusetts General HospitalNot yet recruitingPregnancy Complications | Preeclampsia | Hypertensive Disorders of Pregnancy (HDP) | Aspirin ProphylaxisUnited States
-
University of ManchesterManchester University NHS Foundation TrustCompleted
-
University of Colorado, DenverRecruitingHypoxia | Respiratory Failure | Hypoxemia | Acute Hypoxemic Respiratory Failure | Hypoxic Respiratory Failure | Acute Hypoxic Respiratory FailureUnited States
-
Khon Kaen UniversityCompleted
-
National Institute of Allergy and Infectious Diseases...Centers for Disease Control and PreventionCompleted
-
Johns Hopkins Bloomberg School of Public HealthEnrolling by invitation
-
University of Illinois at ChicagoNational Institute of Mental Health (NIMH)Not yet recruiting
-
Kaiser PermanenteGarfield Memorial FundNot yet recruitingHeart Failure | Iron Deficiency (ID) | Heart Failure and Reduced Ejection Fraction | Heart Failure and Mildly Reduced Ejection FractionUnited States